Navigation Links
FDA Advisers Say Avastin Shouldn't Be Used for Breast Cancer
Date:7/21/2010

TUESDAY, July 20 (HealthDay News) -- The cancer drug Avastin should no longer be used as a treatment for breast cancer, a U.S. Food and Drug Administration advisory panel voted Tuesday, saying the drug wasn't benefiting patients.

The 12 to 1 vote represented a setback for Avastin, which is the world's best-selling cancer drug, with sales last year of about $6 billion. Avastin is sold by drug maker Roche's Genentech unit, The New York Times reported.

Earlier Tuesday, the advisory committee said data suggested that at least for breast cancer, the initial data that led to accelerated approval of Avastin in 2008 for breast cancer was not borne out by subsequent studies.

The drug is also approved for lung, colon, kidney and brain cancer, the Associated Press reported.

The 13 experts convened by the FDA voted unanimously that the drug's side effects and risks outweighed benefits when used with conventional chemotherapy.

When the FDA approved Avastin for breast cancer patients in 2008, it was on the condition that Roche provide additional studies supporting evidence that the drug kept the disease from worsening for more than five months.

But two follow-up studies failed to show that same effect, and patients did not gain any survival benefits. But they did experience serious side effects, including fatigue, abnormal white blood cell counts and high blood pressure, the AP reported.

"The study shows there's very little benefit to patients with significant toxicity risks and no clear survival benefit," said Natalie Compagni Portis, the FDA advisory panel's patient representative, the news service reported.

The FDA is not bound to follow the recommendations of its advisory committees, but typically does so.

More information

To learn more about Avastin, visit the U.S. National Library of Medicine.

-- HealthDay staff

SOURCES: U.S. Food and Drug Administration; The New York Times; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA to Broaden Disclosure on Advisers Conflicts of Interest
2. FDA Advisers Urge Stricter Regulation of Tanning Beds
3. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
4. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
5. Susan G. Komen awards Case Western Reserve nearly $500,000 to study breast cancer in older women
6. Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer
7. Experts Issue New Guidelines on Breast Cancer Drugs
8. Radiation device allows for targeted breast radiation to control cancer
9. Scientists reprogram triple-negative breast cancer cells to respond to tamoxifen
10. Fish Oil Supplements Linked to Lower Risk of Breast Cancer: Study
11. Mathematical models for breast cancer detection with microwave tomography are cheaper and less risky
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: